



Research in Vaccine Epidemiology: Immunogenicity, Effectiveness, and Safety

Guest Editors:

Dr. Francesco Paolo Bianchi

Department of Biological Sciences and Human Oncology, University of Bari, Bari, Italy

Prof. Dr. Silvio Tafuri

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy

Deadline for manuscript submissions:

closed (28 November 2024)

Message from the Guest Editors

Vaccines have saved millions of lives and have increased the quality of life of the entire world, reducing the risk of hospitalization and impairment due to infectious diseases, showing a high efficacy, safety, and cost-effectiveness.

In the COVID-19 pandemic era, the attention of national and international public health institutions is almost entirely focused on the management and control of SARS-COV-2, especially in the first pandemic wave, which was characterized by a slowdown in the health services provided to citizens, including vaccinations.

This Special issue is focused on the recent scientific and technical progresses made in this field. We want to collect contributions about the safety, effectiveness, and immunogenicity of vaccinations used in the “real world” in order to have a complete overview of the “vaccination in the real life”.

Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review, highlighting the topics described above.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)